April 11, 2021
Business News

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease


PARIS & NEW YORK–()–Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and potentially life-threatening liver disorder. The trial is expected to commence in early 2021. Terms of the agreement were not disclosed.

In March 2019, the companies announced that Pfizer had acquired a minority…



Click here to view the original article.

Related Posts

You might also like ...

Article feature image
Fed’s Powell: U.S. economy at an ‘inflection point’ – CBS ’60 Minutes’ – Reuters
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
Article feature image
How baseball card mania is colling with the NFT boom to revive Topps and change the game for dealers – CNBC